X

Drug Profile

Research programme: erythropoietin therapeutics - Takeda

Alternative Names: AP 22594; Dimerizer hormone mimetics research programme - Takeda

Latest Information Update: 07 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ARIAD Pharmaceuticals
Class Antianaemics
Mechanism of Action Erythropoiesis stimulants; Gene expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Anaemia

Most Recent Events

16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
12 Nov 2003 Discontinued - Preclinical for Anaemia in USA (PO)
26 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) has been added to the Haematological disorders pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com